Trial Outcomes & Findings for A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC) (NCT NCT00596648)

Last Updated: 2026-01-13

Results Overview

Treatment duration was defined as the number of days from the first dose to the last dose (measured in weeks), including any days of treatment interruption that occurred before the last dose of study drug.

Recruitment status

COMPLETED

Study phase

PHASE1/PHASE2

Target enrollment

92 participants

Primary outcome timeframe

From initial dose up to 160 weeks

Results posted on

2026-01-13

Participant Flow

Participant milestones

Participant milestones
Measure	Phase 1-Cohort 1 75 mg PO qd cabozantinib, 150 mg PO qd erlotinib	Phase 1-Cohort 2A 75 mg PO qd cabozantinib, 100 mg PO qd erlotinib	Phase 1-Cohort 2B 50 mg PO qd cabozantinib, 150 mg PO qd erlotinib	Phase 1-Cohort 3A 125 mg PO qd cabozantinib, 100 mg PO qd erlotinib	Phase 1-Cohort 4A 125 mg PO qd cabozantinib, 50 mg PO qd erlotinib	Phase 2-cabozantinib single agent cabozantinib 125 mg PO qd	Phase 2-Cabozantinib + Erlotinib 125 mg cabozantinib qd and 50 mg erlotinib
Overall Study STARTED	3	15	17	15	14	15	13
Overall Study COMPLETED	3	14	17	15	14	15	13
Overall Study NOT COMPLETED	0	1	0	0	0	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Phase 1-Cohort 1 n=3 Participants 75 mg PO qd cabozantinib, 150 mg PO qd erlotinib	Phase 1-Cohort 2A n=15 Participants 75 mg PO qd cabozantinib, 100 mg PO qd erlotinib	Phase 1-Cohort 2B n=17 Participants 50 mg PO qd cabozantinib, 150 mg PO qd erlotinib	Phase 1-Cohort 3A n=15 Participants 125 mg PO qd cabozantinib, 100 mg PO qd erlotinib	Phase 1-Cohort 4A n=14 Participants 125 mg PO qd cabozantinib, 50 mg PO qd erlotinib	Phase 2-cabozantinib n=15 Participants cabozantinib single agent 125 mg	Phase 2-cabozantinib + Erlotinib n=13 Participants 125 mg cabozantinib qd and 50 mg erlotinib	Total n=92 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=210 Participants	0 Participants n=19 Participants	0 Participants n=123 Participants	0 Participants n=123 Participants	0 Participants n=615 Participants	0 Participants n=20 Participants	0 Participants n=13 Participants	0 Participants n=335 Participants
Age, Categorical Between 18 and 65 years	2 Participants n=210 Participants	8 Participants n=19 Participants	12 Participants n=123 Participants	12 Participants n=123 Participants	7 Participants n=615 Participants	12 Participants n=20 Participants	7 Participants n=13 Participants	60 Participants n=335 Participants
Age, Categorical >=65 years	1 Participants n=210 Participants	7 Participants n=19 Participants	5 Participants n=123 Participants	3 Participants n=123 Participants	7 Participants n=615 Participants	3 Participants n=20 Participants	6 Participants n=13 Participants	32 Participants n=335 Participants
Age, Continuous	56.1 years n=210 Participants	61.6 years n=19 Participants	61.4 years n=123 Participants	57 years n=123 Participants	64.5 years n=615 Participants	54.7 years n=20 Participants	64.8 years n=13 Participants	59.8 years n=335 Participants
Sex: Female, Male Female	3 Participants n=210 Participants	9 Participants n=19 Participants	13 Participants n=123 Participants	10 Participants n=123 Participants	9 Participants n=615 Participants	12 Participants n=20 Participants	7 Participants n=13 Participants	63 Participants n=335 Participants
Sex: Female, Male Male	0 Participants n=210 Participants	6 Participants n=19 Participants	4 Participants n=123 Participants	5 Participants n=123 Participants	5 Participants n=615 Participants	3 Participants n=20 Participants	6 Participants n=13 Participants	29 Participants n=335 Participants

PRIMARY outcome

Timeframe: From initial dose up to 160 weeks

Population: Safety Population was defined as all participants who received at least one dose of cabozantinib.

Outcome measures

Outcome measures
Measure	Phase 1 - Cohort 1 n=3 Participants cabozantinib 75mg po QD, plus erlotinib 150mg po QD	Phase 1 - Cohort 2A n=15 Participants cabozantinib 75mg po QD, plus erlotinib 100mg po QD	Phase 1 - Cohort 2B n=17 Participants cabozantinib 50mg po QD, plus erlotinib 150mg po QD	Phase 1 - Cohort 3A n=15 Participants cabozantinib 125mg po QD, plus erlotinib 100mg po QD	Phase 1 - Cohort 4A n=14 Participants cabozantinib 125mg po QD, plus erlotinib 50mg po QD
Phase 1: Duration of Exposure of Cabozantinib With Erlotinib Cabozantinib (XL184)	4.43 Weeks Interval 3.0 to 7.1	8.14 Weeks Interval 2.1 to 143.6	8.00 Weeks Interval 0.4 to 156.7	17.00 Weeks Interval 6.1 to 80.3	20.07 Weeks Interval 4.9 to 57.0
Phase 1: Duration of Exposure of Cabozantinib With Erlotinib Erlotinib	6.57 Weeks Interval 5.0 to 9.0	10.29 Weeks Interval 4.1 to 146.3	10.00 Weeks Interval 2.4 to 158.7	22.00 Weeks Interval 8.9 to 84.3	22.07 Weeks Interval 6.9 to 54.7

PRIMARY outcome

Timeframe: From initial dose up to 72 weeks

Population: ORR was assessed using the efficacy measurable population.

Objective Response Rate is defined as the number of participants for whom the best overall response is complete (CR) or partial response (PR) confirmed by repeat assessments no less than four weeks after the criteria for the initial response were first met.

Outcome measures

Outcome measures
Measure	Phase 1 - Cohort 1 n=15 Participants cabozantinib 75mg po QD, plus erlotinib 150mg po QD	Phase 1 - Cohort 2A n=13 Participants cabozantinib 75mg po QD, plus erlotinib 100mg po QD	Phase 1 - Cohort 2B cabozantinib 50mg po QD, plus erlotinib 150mg po QD	Phase 1 - Cohort 3A cabozantinib 125mg po QD, plus erlotinib 100mg po QD	Phase 1 - Cohort 4A cabozantinib 125mg po QD, plus erlotinib 50mg po QD
Phase 2: Objective Response Rate (ORR)	1 Participants	0 Participants	—	—	—

SECONDARY outcome

Timeframe: From initial dose up to 72 weeks

Population: Safety Population was defined as all participants who received at least one dose of cabozantinib. 'Overall number of participants analyzed' = participants evaluable for this Outcome Measure. There were zero responders in Phase 2 - ARM 2, Cabozantinib + Erlotinib arm. So, no data was derived for this endpoint for this arm.

DOR was defined as the time interval from the first documentation of CR or PR to the earlier of the first documentation of definitive disease progression or death from any cause.

Outcome measures

Outcome measures
Measure	Phase 1 - Cohort 1 n=1 Participants cabozantinib 75mg po QD, plus erlotinib 150mg po QD	Phase 1 - Cohort 2A cabozantinib 75mg po QD, plus erlotinib 100mg po QD	Phase 1 - Cohort 2B cabozantinib 50mg po QD, plus erlotinib 150mg po QD	Phase 1 - Cohort 3A cabozantinib 125mg po QD, plus erlotinib 100mg po QD	Phase 1 - Cohort 4A cabozantinib 125mg po QD, plus erlotinib 50mg po QD
Phase 2: Duration of Response (DOR) in Participants With a CR or PR	NA Weeks Per prespecified analysis in the Statistical Analysis Plan, 90% confidence interval was not collected. The DOR for the single participant is not disclosed to protect patient confidentiality.	—	—	—	—

SECONDARY outcome

Timeframe: From initial dose up to 72 weeks

Progression-free survival is defined as the time from first dose of cabozantinib to disease progression per protocol-defined criteria or death due to any cause, whichever occurs first.

Outcome measures

Outcome measures
Measure	Phase 1 - Cohort 1 n=15 Participants cabozantinib 75mg po QD, plus erlotinib 150mg po QD	Phase 1 - Cohort 2A n=13 Participants cabozantinib 75mg po QD, plus erlotinib 100mg po QD	Phase 1 - Cohort 2B cabozantinib 50mg po QD, plus erlotinib 150mg po QD	Phase 1 - Cohort 3A cabozantinib 125mg po QD, plus erlotinib 100mg po QD	Phase 1 - Cohort 4A cabozantinib 125mg po QD, plus erlotinib 50mg po QD
Phase 2: Progression-Free Survival (PFS)	1.91 months Interval 1.64 to 7.06	3.94 months Interval 1.54 to 7.26	—	—	—

Adverse Events

Phase 1 - Cohort 1

Serious events: 1 serious events

Other events: 3 other events

Deaths: 0 deaths

Phase 1 - Cohort 2A

Serious events: 7 serious events

Other events: 15 other events

Deaths: 0 deaths

Phase 1 - Cohort 2B

Serious events: 8 serious events

Other events: 17 other events

Deaths: 0 deaths

Phase 1 - Cohort 3A

Serious events: 8 serious events

Other events: 15 other events

Deaths: 0 deaths

Phase 1 - Cohort 4A

Serious events: 7 serious events

Other events: 14 other events

Deaths: 0 deaths

Phase 2 - ARM 1, Cabozantinib ALONE

Serious events: 5 serious events

Other events: 15 other events

Deaths: 0 deaths

Phase 2 - ARM 2, Cabozantinib + Erlotinib

Serious events: 11 serious events

Other events: 12 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Phase 1 - Cohort 1 n=3 participants at risk cabozantinib 75mg po QD, plus erlotinib 150mg po QD	Phase 1 - Cohort 2A n=15 participants at risk cabozantinib 75mg po QD, plus erlotinib 100mg po QD	Phase 1 - Cohort 2B n=17 participants at risk cabozantinib 50mg po QD, plus erlotinib 150mg po QD	Phase 1 - Cohort 3A n=15 participants at risk cabozantinib 125mg po QD, plus erlotinib 100mg po QD	Phase 1 - Cohort 4A n=14 participants at risk cabozantinib 125mg po QD, plus erlotinib 50mg po QD	Phase 2 - ARM 1, Cabozantinib ALONE n=15 participants at risk cabozantinib 125mg po QD	Phase 2 - ARM 2, Cabozantinib + Erlotinib n=13 participants at risk cabozantinib 125mg po QD + erlotinib 50mg po QD
Blood and lymphatic system disorders NEUTROPENIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Blood and lymphatic system disorders THROMBOCYTOPENIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Cardiac disorders ACUTE MYOCARDIAL INFARCTION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Cardiac disorders ATRIAL FIBRILLATION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders DIARRHOEA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	15.4% 2/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders ABDOMINAL PAIN	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders VOMITING	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders LARGE INTESTINE PERFORATION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders NAUSEA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
General disorders GAIT DISTURBANCE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
General disorders NON-CARDIAC CHEST PAIN	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Hepatobiliary disorders HEPATIC FAILURE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Infections and infestations PNEUMONIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Infections and infestations BRONCHITIS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Injury, poisoning and procedural complications BRAIN HERNIATION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Injury, poisoning and procedural complications FEMUR FRACTURE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Injury, poisoning and procedural complications HUMERUS FRACTURE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations INTERNATIONAL NORMALISED RATIO INCREASED	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations NEUTROPHIL COUNT DECREASED	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Metabolism and nutrition disorders DEHYDRATION	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	11.8% 2/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	23.1% 3/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
General disorders FATIGUE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Metabolism and nutrition disorders HYPONATRAEMIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Metabolism and nutrition disorders HYPERKALAEMIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Metabolism and nutrition disorders HYPOKALAEMIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Musculoskeletal and connective tissue disorders BACK PAIN	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	11.8% 2/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Musculoskeletal and connective tissue disorders COSTOCHONDRITIS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LUNG NEOPLASM MALIGNANT	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) METASTASES TO CENTRAL NERVOUS SYSTEM	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders DYSARTHRIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders HAEMORRHAGE INTRACRANIAL	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders HAEMORRHAGIC STROKE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders HEADACHE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders INTRAVENTRICULAR HAEMORRHAGE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders TRANSIENT ISCHAEMIC ATTACK	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Psychiatric disorders CONFUSIONAL STATE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Psychiatric disorders MENTAL STATUS CHANGES	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Renal and urinary disorders RENAL FAILURE ACUTE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Renal and urinary disorders NEPHROLITHIASIS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders PULMONARY EMBOLISM	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders DYSPNOEA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders ACUTE RESPIRATORY FAILURE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders EPISTAXIS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders HAEMOPTYSIS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders PNEUMONIA ASPIRATION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders RESPIRATORY ARREST	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders RESPIRATORY FAILURE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Vascular disorders DEEP VEIN THROMBOSIS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Infections and infestations RECTAL ABSCESS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Musculoskeletal and connective tissue disorders OSTENECROSIS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.

Other adverse events

Other adverse events
Measure	Phase 1 - Cohort 1 n=3 participants at risk cabozantinib 75mg po QD, plus erlotinib 150mg po QD	Phase 1 - Cohort 2A n=15 participants at risk cabozantinib 75mg po QD, plus erlotinib 100mg po QD	Phase 1 - Cohort 2B n=17 participants at risk cabozantinib 50mg po QD, plus erlotinib 150mg po QD	Phase 1 - Cohort 3A n=15 participants at risk cabozantinib 125mg po QD, plus erlotinib 100mg po QD	Phase 1 - Cohort 4A n=14 participants at risk cabozantinib 125mg po QD, plus erlotinib 50mg po QD	Phase 2 - ARM 1, Cabozantinib ALONE n=15 participants at risk cabozantinib 125mg po QD	Phase 2 - ARM 2, Cabozantinib + Erlotinib n=13 participants at risk cabozantinib 125mg po QD + erlotinib 50mg po QD
Blood and lymphatic system disorders LYMPHOPENIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	17.6% 3/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	15.4% 2/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Blood and lymphatic system disorders NEUTROPENIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	28.6% 4/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Blood and lymphatic system disorders ANAEMIA	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Blood and lymphatic system disorders LEUKOPENIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Blood and lymphatic system disorders LYMPHADENOPATHY	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	11.8% 2/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Blood and lymphatic system disorders THROMBOCYTOPENIA	66.7% 2/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Blood and lymphatic system disorders GRANULOCYTOPENIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Blood and lymphatic system disorders SPLENIC HAEMORRHAGE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Cardiac disorders SINUS TACHYCARDIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Cardiac disorders TACHYCARDIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Cardiac disorders ARRHYTHMIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Cardiac disorders SUPRAVENTRICULAR BUNDLE BRANCH BLOCK RIGHT	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Cardiac disorders CARDIAC FAILURE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Cardiac disorders PERICARDIAL EFFUSION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Cardiac disorders SINUS ARRHYTHMIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Ear and labyrinth disorders EAR DISCOMFORT	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Ear and labyrinth disorders HYPOACUSIS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Endocrine disorders HYPOTHYROIDISM	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Eye disorders VISION BLURRED	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Eye disorders DRY EYE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	11.8% 2/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Eye disorders EYE DISCHARGE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Eye disorders CONJUNCTIVAL OEDEMA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Eye disorders DIPLOPIA	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Eye disorders EYE PRURITUS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Eye disorders HALO VISION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Eye disorders LACRIMATION INCREASED	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Eye disorders OCULAR ICTERUS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Eye disorders PHOTOPHOBIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders DIARRHOEA	100.0% 3/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	93.3% 14/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	76.5% 13/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	86.7% 13/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	92.9% 13/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	60.0% 9/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	76.9% 10/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders NAUSEA	66.7% 2/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	53.3% 8/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	47.1% 8/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	80.0% 12/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	64.3% 9/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	60.0% 9/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	53.8% 7/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders VOMITING	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	26.7% 4/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	47.1% 8/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	40.0% 6/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	42.9% 6/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	33.3% 5/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	30.8% 4/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders CONSTIPATION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	46.7% 7/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	35.7% 5/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	40.0% 6/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	15.4% 2/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders ABDOMINAL PAIN	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	42.9% 6/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders DRY MOUTH	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	11.8% 2/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	28.6% 4/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders STOMATITIS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	17.6% 3/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	21.4% 3/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders ABDOMINAL DISTENSION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	26.7% 4/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders DYSPEPSIA	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	28.6% 4/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders HAEMORRHOIDS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	21.4% 3/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders ABDOMINAL PAIN UPPER	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	11.8% 2/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders DYSPHAGIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	15.4% 2/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders FLATULENCE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders GINGIVAL BLEEDING	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders ORAL PAIN	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders ABDOMINAL DISCOMFORT	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders ERUCTATION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders GASTROOESOPHAGEAL REFLUX DISEASE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders GLOSSODYNIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders ABDOMINAL TENDERNESS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders ANORECTAL DISORDER	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders APHTHOUS STOMATITIS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders CHAPPED LIPS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders GASTROINTESTINAL DISORDER	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders GINGIVAL CYST	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders GINGIVAL ERYTHEMA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders GINGIVAL PAIN	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders HAEMATOCHEZIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders MOUTH ULCERATION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders ORAL DISCOMFORT	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders ORAL DISORDER	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders ORAL MUCOSAL ERYTHEMA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders PANCREATIC MASS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders PROCTALGIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders RECTAL HAEMORRHAGE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders RETCHING	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders SWOLLEN TONGUE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders TONGUE ULCERATION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Gastrointestinal disorders UPPER GASTROINTESTINAL HAEMORRHAGE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
General disorders FATIGUE	100.0% 3/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	60.0% 9/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	52.9% 9/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	66.7% 10/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	71.4% 10/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	86.7% 13/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	76.9% 10/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
General disorders OEDEMA PERIPHERAL	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	41.2% 7/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	28.6% 4/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	23.1% 3/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
General disorders CHEST PAIN	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	21.4% 3/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	26.7% 4/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
General disorders MUCOSAL INFLAMMATION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	23.1% 3/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
General disorders ASTHENIA	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
General disorders CHEST DISCOMFORT	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
General disorders CHILLS	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
General disorders NON-CARDIAC CHEST PAIN	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
General disorders PAIN	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	11.8% 2/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
General disorders PYREXIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
General disorders EARLY SATIETY	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
General disorders GAIT DISTURBANCE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
General disorders LOCAL SWELLING	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
General disorders OEDEMA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
General disorders SPINAL PAIN	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
General disorders SUPRAPUBIC PAIN	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
General disorders XEROSIS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Hepatobiliary disorders HYPERBILIRUBINAEMIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Immune system disorders SEASONAL ALLERGY	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Infections and infestations URINARY TRACT INFECTION	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	17.6% 3/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	26.7% 4/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Infections and infestations UPPER RESPIRATORY TRACT INFECTION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Infections and infestations PNEUMONIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	11.8% 2/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Infections and infestations PARONYCHIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	11.8% 2/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Infections and infestations CANDIDIASIS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Infections and infestations PHARYNGITIS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Infections and infestations CELLULITIS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Infections and infestations DIVERTICULITIS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Infections and infestations EYE INFECTION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Infections and infestations FUNGAL SKIN INFECTION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Infections and infestations HERPES VIRUS INFECTION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Infections and infestations LARYNGITIS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Infections and infestations LOCALISED INFECTION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Infections and infestations LUNG INFECTION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Infections and infestations ORAL HERPES	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Infections and infestations PERIRECTAL ABSCESS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Infections and infestations SINUSITIS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Infections and infestations TRACHEITIS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Infections and infestations VIRAL UPPER RESPIRATORY TRACT INFECTION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Injury, poisoning and procedural complications CONTUSION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	21.4% 3/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Injury, poisoning and procedural complications FALL	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Injury, poisoning and procedural complications ARTHROPOD BITE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Injury, poisoning and procedural complications CORNEAL ABRASION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Injury, poisoning and procedural complications EXCORIATION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Injury, poisoning and procedural complications FACE INJURY	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Injury, poisoning and procedural complications INCISION SITE PAIN	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Injury, poisoning and procedural complications PROCEDURAL PAIN	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Injury, poisoning and procedural complications TONGUE INJURY	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Injury, poisoning and procedural complications WOUND	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations WEIGHT DECREASED	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	40.0% 6/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	41.2% 7/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	46.7% 7/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	50.0% 7/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	40.0% 6/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	30.8% 4/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations BREATH SOUNDS ABNORMAL	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	23.5% 4/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	26.7% 4/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	23.1% 3/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations LIPASE INCREASED	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	17.6% 3/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	26.7% 4/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations ASPARTATE AMINOTRANSFERASE INCREASED	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	26.7% 4/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations BLOOD ALKALINE PHOSPHATASE INCREASED	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	11.8% 2/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations BLOOD LACTATE DEHYDROGENASE INCREASED	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	17.6% 3/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations ALANINE AMINOTRANSFERASE INCREASED	100.0% 3/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations BLOOD UREA INCREASED	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations BLOOD MAGNESIUM DECREASED	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations BLOOD PHOSPHORUS DECREASED	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations WHITE BLOOD CELL COUNT DECREASED	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	17.6% 3/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations BLOOD ALBUMIN DECREASED	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations BLOOD CREATININE INCREASED	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	17.6% 3/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations PLATELET COUNT DECREASED	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	11.8% 2/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations TRANSAMINASES INCREASED	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations AMYLASE INCREASED	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations BLOOD CHLORIDE DECREASED	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations HAEMOGLOBIN DECREASED	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations INTERNATIONAL NORMALISED RATIO INCREASED	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	11.8% 2/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations PROTHROMBIN TIME PROLONGED	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	11.8% 2/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations BACTERIAL TEST POSITIVE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations BLOOD BILIRUBIN DECREASED	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations BLOOD CALCIUM DECREASED	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations BLOOD CREATINE PHOSPHOKINASE MB INCREASED	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations BLOOD POTASSIUM DECREASED	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations BLOOD URINE PRESENT	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations CARDIAC MURMUR	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations LYMPH NODE PALPABLE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations NEUTROPHIL COUNT DECREASED	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations PLATELET COUNT INCREASED	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations RED CELL DISTRIBUTION WIDTH INCREASED	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations RESPIRATORY RATE INCREASED	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations SKIN TURGOR DECREASED	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Investigations URINE LEUKOCYTE ESTERASE POSITIVE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Metabolism and nutrition disorders DECREASED APPETITE	66.7% 2/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	46.7% 7/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	64.7% 11/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	66.7% 10/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	78.6% 11/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	53.3% 8/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	38.5% 5/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Metabolism and nutrition disorders DEHYDRATION	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	33.3% 5/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	23.5% 4/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	40.0% 6/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	21.4% 3/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	30.8% 4/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Metabolism and nutrition disorders HYPOMAGNESAEMIA	66.7% 2/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	26.7% 4/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	11.8% 2/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	40.0% 6/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	35.7% 5/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	30.8% 4/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Metabolism and nutrition disorders HYPOKALAEMIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	23.1% 3/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders HEADACHE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	11.8% 2/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	33.3% 5/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	28.6% 4/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	26.7% 4/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	30.8% 4/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Metabolism and nutrition disorders HYPONATRAEMIA	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	11.8% 2/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	21.4% 3/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Metabolism and nutrition disorders HYPOPHOSPHATAEMIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	40.0% 6/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	21.4% 3/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	15.4% 2/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Metabolism and nutrition disorders HYPOALBUMINAEMIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	23.5% 4/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Metabolism and nutrition disorders HYPERGLYCAEMIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Metabolism and nutrition disorders HYPOCALCAEMIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Metabolism and nutrition disorders HYPERCALCAEMIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Metabolism and nutrition disorders HYPERMAGNESAEMIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Metabolism and nutrition disorders HYPERAMYLASAEMIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Metabolism and nutrition disorders HYPERKALAEMIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Metabolism and nutrition disorders HYPERLIPASAEMIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Metabolism and nutrition disorders HYPERNATRAEMIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Metabolism and nutrition disorders HYPOGLYCAEMIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders DYSKINESIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Musculoskeletal and connective tissue disorders PAIN IN EXTREMITY	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	17.6% 3/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	15.4% 2/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Musculoskeletal and connective tissue disorders MYALGIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	17.6% 3/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	33.3% 5/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Musculoskeletal and connective tissue disorders MUSCULOSKELETAL PAIN	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Musculoskeletal and connective tissue disorders ARTHRALGIA	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Musculoskeletal and connective tissue disorders MUSCLE SPASMS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	21.4% 3/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Musculoskeletal and connective tissue disorders MUSCULOSKELETAL CHEST PAIN	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Musculoskeletal and connective tissue disorders BACK PAIN	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	11.8% 2/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Musculoskeletal and connective tissue disorders BONE PAIN	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Musculoskeletal and connective tissue disorders MUSCULAR WEAKNESS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Musculoskeletal and connective tissue disorders NECK PAIN	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Musculoskeletal and connective tissue disorders ARTHROPATHY	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Musculoskeletal and connective tissue disorders JOINT SWELLING	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Musculoskeletal and connective tissue disorders LIMB DISCOMFORT	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Musculoskeletal and connective tissue disorders MUSCLE TIGHTNESS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) MELANOCYTIC NAEVUS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders DYSGEUSIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	23.5% 4/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	53.3% 8/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	42.9% 6/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	23.1% 3/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders DIZZINESS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	33.3% 5/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	17.6% 3/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	40.0% 6/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	50.0% 7/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders HYPOAESTHESIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders NEUROPATHY PERIPHERAL	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders PARAESTHESIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	11.8% 2/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders PERIPHERAL SENSORY NEUROPATHY	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders SINUS HEADACHE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders AGEUSIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders APHASIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders BALANCE DISORDER	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders BRAIN OEDEMA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders BURNING SENSATION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders COGNITIVE DISORDER	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders CRANIAL NERVE DISORDER	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders DYSARTHRIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders LETHARGY	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders NEURALGIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders PERIPHERAL MOTOR NEUROPATHY	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders PRESYNCOPE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders SPEECH DISORDER	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders SYNCOPE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders TONGUE PARALYSIS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders VIITH NERVE PARALYSIS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Nervous system disorders VISUAL FIELD DEFECT	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Psychiatric disorders ANXIETY	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	17.6% 3/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Psychiatric disorders DEPRESSION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	17.6% 3/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Psychiatric disorders INSOMNIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	26.7% 4/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Psychiatric disorders CONFUSIONAL STATE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Psychiatric disorders ANHEDONIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Psychiatric disorders AGITATION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Psychiatric disorders DELIRIUM	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Psychiatric disorders HALLUCINATION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Psychiatric disorders MENTAL STATUS CHANGES	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Psychiatric disorders SLEEP DISORDER	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Psychiatric disorders SOMNAMBULISM	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Renal and urinary disorders DYSURIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Renal and urinary disorders HAEMATURIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Renal and urinary disorders NOCTURIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Renal and urinary disorders PROTEINURIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Renal and urinary disorders URINARY INCONTINENCE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Renal and urinary disorders AZOTAEMIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Renal and urinary disorders MICTURITION URGENCY	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Renal and urinary disorders RENAL FAILURE ACUTE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	11.8% 2/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Renal and urinary disorders URINARY RETENTION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Reproductive system and breast disorders VAGINAL DISCHARGE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Reproductive system and breast disorders BARTHOLIN'S CYST	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Reproductive system and breast disorders GENITAL LESION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Reproductive system and breast disorders GENITAL RASH	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Reproductive system and breast disorders METRORRHAGIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Reproductive system and breast disorders VAGINAL HAEMORRHAGE	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Reproductive system and breast disorders VULVOVAGINAL PRURITUS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders DYSPNOEA	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	35.3% 6/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	26.7% 4/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	50.0% 7/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	26.7% 4/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders COUGH	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	26.7% 4/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	26.7% 4/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	42.9% 6/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	53.3% 8/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders DYSPHONIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	26.7% 4/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	11.8% 2/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	23.1% 3/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders OROPHARYNGEAL PAIN	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	15.4% 2/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders HYPOXIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	17.6% 3/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders HAEMOPTYSIS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	11.8% 2/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders PLEURAL EFFUSION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders DYSPNOEA EXERTIONAL	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	11.8% 2/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders EPISTAXIS	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders PRODUCTIVE COUGH	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders RHINITIS ALLERGIC	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders RHINORRHOEA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders HICCUPS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders RALES	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders BRONCHOSPASM	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders DRY THROAT	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders NASAL DISCOMFORT	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders OROPHARYNGEAL DISCOMFORT	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders PLEURITIC PAIN	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders SINUS CONGESTION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Respiratory, thoracic and mediastinal disorders SNEEZING	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders RASH	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	60.0% 9/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	41.2% 7/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	40.0% 6/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	28.6% 4/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	30.8% 4/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	40.0% 6/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	30.8% 4/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders DRY SKIN	66.7% 2/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	26.7% 4/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	28.6% 4/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	40.0% 6/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders ALOPECIA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	23.1% 3/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders PRURITUS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	21.4% 3/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders ERYTHEMA	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	11.8% 2/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders DERMATITIS ACNEIFORM	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	11.8% 2/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders HAIR COLOUR CHANGES	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders BLISTER	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders EXFOLIATIVE RASH	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders NAIL DISORDER	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	13.3% 2/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders NIGHT SWEATS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders SKIN FISSURES	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders SKIN ULCER	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders DECUBITUS ULCER	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders DERMATITIS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders HYPERHIDROSIS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders HYPERTRICHOSIS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders NAIL BED TENDERNESS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders RASH ERYTHEMATOUS	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders RASH PRURITIC	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders SKIN DISORDER	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders SKIN EXFOLIATION	33.3% 1/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders SKIN HYPOPIGMENTATION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Skin and subcutaneous tissue disorders SKIN LESION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.7% 1/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Vascular disorders HYPERTENSION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	26.7% 4/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	30.8% 4/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Vascular disorders HOT FLUSH	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	5.9% 1/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Vascular disorders FLUSHING	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	7.1% 1/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	6.7% 1/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.
Vascular disorders HYPOTENSION	0.00% 0/3 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	26.7% 4/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/17 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	20.0% 3/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	14.3% 2/14 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/15 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.	0.00% 0/13 • From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks) Safety Population was defined as all participants who received at least one dose of cabozantinib.

Additional Information

Exelixis Medical Information

Exelixis, Inc.

Phone: 855-292-3935

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place